D&D Research

D&D Pharmatech is a South Korean clinical-stage biotechnology company focused on developing innovative treatments for metabolic, neurodegenerative, and fibrotic diseases. The company utilizes a multi-subsidiary model, with US-based entities like Neuraly and Precision Molecular leading specific therapeutic areas. Its core pipeline includes long-acting GLP-1 receptor agonists and dual agonists, such as DD01 for MASH and NLY01 for Parkinson's disease. D&D Pharmatech recently went public on the KOSDAQ exchange in 2024 and has established significant global partnerships, notably with Metsera, to advance its oral and injectable metabolic programs. The company's approach combines deep expertise in peptide engineering with advanced imaging and sequencing technologies to address high unmet medical needs.